You do not have access to the full text of this article, the first page of the PDF of this article appears above. This article requires a subscription to view the full text. If you have a subscription ...

Journal of Nuclear Medicine Technology August 2026, jnmt.126.272098; DOI: https://doi.org/10.2967/jnmt.126.272098 ...

Journal of Nuclear Medicine Technology June 2026, jnmt.126.272186; DOI: https://doi.org/10.2967/jnmt.126.272186 ...

Journal of Nuclear Medicine Technology June 2026, jnmt.126.272159; DOI: https://doi.org/10.2967/jnmt.126.272159 ...

Journal of Nuclear Medicine Technology June 2026, jnmt.126.272432; DOI: https://doi.org/10.2967/jnmt.126.272432 ...

Myocardial perfusion scintigraphy and 2-dimensional (2D) echocardiography are used for evaluating left ventricular function and ejection fraction (EF). This study aimed to validate the ...

Journal of Nuclear Medicine Technology June 2026, jnmt.125.271607; DOI: https://doi.org/10.2967/jnmt.125.271607 ...

Today’s common practice of empiric activity prescription in radiopharmaceutical therapy is inconsistent with the modern philosophy of personalized medicine. We investigate the radiobiologic ...

Prostate-specific membrane antigen (PSMA) has fundamentally reshaped prostate cancer imaging and therapy, delivering an unprecedented combination of high lesion conspicuity, broad clinical ...

Prostate cancer is a rapidly expanding area for radiopharmaceutical therapy, primarily driven by prostate-specific membrane antigen–targeted imaging and therapy. This growth necessitates new workflows ...

The Prostate Cancer Working Group 4 guidelines (PCWG4) represent a significant evolution in the framework used to evaluate prostate cancer progression and treatment response in clinical trials.

Journal of Nuclear Medicine Technology April 2026, jnmt.125.271114; DOI: https://doi.org/10.2967/jnmt.125.271114 ...